JP4605800B2 - 新規化合物および治療におけるその使用 - Google Patents
新規化合物および治療におけるその使用 Download PDFInfo
- Publication number
- JP4605800B2 JP4605800B2 JP2006515869A JP2006515869A JP4605800B2 JP 4605800 B2 JP4605800 B2 JP 4605800B2 JP 2006515869 A JP2006515869 A JP 2006515869A JP 2006515869 A JP2006515869 A JP 2006515869A JP 4605800 B2 JP4605800 B2 JP 4605800B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- benzo
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 507
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 237
- 125000001424 substituent group Chemical group 0.000 claims description 177
- -1 Dioxolyl Chemical group 0.000 claims description 164
- 229910052736 halogen Inorganic materials 0.000 claims description 129
- 125000003118 aryl group Chemical group 0.000 claims description 128
- 229910052739 hydrogen Inorganic materials 0.000 claims description 128
- 239000001257 hydrogen Substances 0.000 claims description 128
- 150000002367 halogens Chemical class 0.000 claims description 112
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 111
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 99
- 125000001072 heteroaryl group Chemical group 0.000 claims description 97
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 69
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 68
- 201000010099 disease Diseases 0.000 claims description 61
- 125000004122 cyclic group Chemical group 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 50
- 125000004043 oxo group Chemical group O=* 0.000 claims description 44
- 230000001419 dependent effect Effects 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 38
- 125000001544 thienyl group Chemical group 0.000 claims description 38
- 125000004076 pyridyl group Chemical group 0.000 claims description 35
- 125000002541 furyl group Chemical group 0.000 claims description 34
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- 150000002825 nitriles Chemical class 0.000 claims description 29
- 239000003270 steroid hormone Substances 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000004104 aryloxy group Chemical group 0.000 claims description 24
- 125000001624 naphthyl group Chemical group 0.000 claims description 24
- 150000001408 amides Chemical class 0.000 claims description 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 23
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 21
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 20
- 125000004414 alkyl thio group Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 201000010260 leiomyoma Diseases 0.000 claims description 19
- 201000009273 Endometriosis Diseases 0.000 claims description 18
- 150000002430 hydrocarbons Chemical group 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 18
- 125000002757 morpholinyl group Chemical group 0.000 claims description 17
- 125000003386 piperidinyl group Chemical group 0.000 claims description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 17
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 17
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 16
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 16
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 125000001246 bromo group Chemical group Br* 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 15
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 15
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 14
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 13
- 239000004305 biphenyl Substances 0.000 claims description 13
- 235000010290 biphenyl Nutrition 0.000 claims description 13
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 13
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 13
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- 125000000335 thiazolyl group Chemical group 0.000 claims description 13
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 12
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 125000004423 acyloxy group Chemical group 0.000 claims description 11
- 125000005110 aryl thio group Chemical group 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 10
- 125000003725 azepanyl group Chemical group 0.000 claims description 10
- 125000002393 azetidinyl group Chemical group 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 125000002883 imidazolyl group Chemical group 0.000 claims description 10
- 125000001041 indolyl group Chemical group 0.000 claims description 10
- 125000005961 oxazepanyl group Chemical group 0.000 claims description 10
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 10
- 125000004193 piperazinyl group Chemical group 0.000 claims description 10
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 10
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 10
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 10
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 9
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 9
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 9
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000002971 oxazolyl group Chemical group 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 9
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 125000005251 aryl acyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 201000007954 uterine fibroid Diseases 0.000 claims description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 7
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 7
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000005959 diazepanyl group Chemical group 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000001680 trimethoxyphenyl group Chemical group 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 208000005641 Adenomyosis Diseases 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010020112 Hirsutism Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010046788 Uterine haemorrhage Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 201000009274 endometriosis of uterus Diseases 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000007106 menorrhagia Diseases 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 230000001568 sexual effect Effects 0.000 claims description 6
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 206010036590 Premature baby Diseases 0.000 claims description 5
- 206010039792 Seborrhoea Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 5
- 201000002996 androgenic alopecia Diseases 0.000 claims description 5
- 201000006828 endometrial hyperplasia Diseases 0.000 claims description 5
- 230000001788 irregular Effects 0.000 claims description 5
- 239000002583 male contraceptive agent Substances 0.000 claims description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 5
- 201000007094 prostatitis Diseases 0.000 claims description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 5
- 230000021595 spermatogenesis Effects 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical group O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 4
- XHHYIAWXOGUEII-UHFFFAOYSA-N 2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(2-methylpropyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC(C)C)=C1Br XHHYIAWXOGUEII-UHFFFAOYSA-N 0.000 claims description 4
- DRJKOQOGSXDPKO-UHFFFAOYSA-N 2-(2-chloro-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(2-methylbutyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1Cl DRJKOQOGSXDPKO-UHFFFAOYSA-N 0.000 claims description 4
- QCKAVYPIXVSRIP-UHFFFAOYSA-N 2-(2-chloro-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(oxolan-2-ylmethyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC2OCCC2)=C1Cl QCKAVYPIXVSRIP-UHFFFAOYSA-N 0.000 claims description 4
- BLRNHMUGGSGEFC-UHFFFAOYSA-N 2-(8-hydroxy-4-oxo-2-thiophen-2-yl-[1]benzothiolo[2,3-d]pyrimidin-3-yl)ethyl thiophene-2-carboxylate Chemical compound OC1=CC=CC(C=2C(=O)N3CCOC(=O)C=4SC=CC=4)=C1SC=2N=C3C1=CC=CS1 BLRNHMUGGSGEFC-UHFFFAOYSA-N 0.000 claims description 4
- DCLCVMZXAZXDIA-UHFFFAOYSA-N 3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-propyl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CCCC1=NC=2SC3=C(O)C=CC=C3C=2C(=O)N1CC1=CC=C(Br)O1 DCLCVMZXAZXDIA-UHFFFAOYSA-N 0.000 claims description 4
- BYLUGBTVNKWOOP-UHFFFAOYSA-N 3-benzyl-2-(2-chloro-3,4,5-trimethoxyphenyl)-8-hydroxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1Cl BYLUGBTVNKWOOP-UHFFFAOYSA-N 0.000 claims description 4
- IHFCTBYGNJBHLU-UHFFFAOYSA-N 3-benzyl-2-(4-methoxyphenyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C1=CC=C(C=O)C=C1S2 IHFCTBYGNJBHLU-UHFFFAOYSA-N 0.000 claims description 4
- PLMIWUYUHDKIOU-UHFFFAOYSA-N 3-benzyl-8-ethylsulfanyl-2-(4-methoxyphenyl)-4-oxo-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound CCSC1=C(C=O)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=C(OC)C=C1 PLMIWUYUHDKIOU-UHFFFAOYSA-N 0.000 claims description 4
- GOBGXFNVRDORKE-UHFFFAOYSA-N 3-benzyl-8-ethylsulfanyl-2-(4-methoxyphenyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound CCSC1=C(C=O)C=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=C(OC)C=C1 GOBGXFNVRDORKE-UHFFFAOYSA-N 0.000 claims description 4
- XPTDTOFYTCYHSF-UHFFFAOYSA-N 3-benzyl-8-hydroxy-2-thiophen-2-yl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OC1=CC=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CS1 XPTDTOFYTCYHSF-UHFFFAOYSA-N 0.000 claims description 4
- HHBJKZCQWKMHNL-UHFFFAOYSA-N 3-butyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CCCC)C=1C1=CC(OC)=C(OC)C(OC)=C1 HHBJKZCQWKMHNL-UHFFFAOYSA-N 0.000 claims description 4
- FVCXLTHFQRFWJY-UHFFFAOYSA-N 5-bromo-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4Br)=O)SC=3N=2)CC(C)C)=C1 FVCXLTHFQRFWJY-UHFFFAOYSA-N 0.000 claims description 4
- FBFTVBPTKNXUJZ-UHFFFAOYSA-N 7-bromo-3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1 FBFTVBPTKNXUJZ-UHFFFAOYSA-N 0.000 claims description 4
- RSKOJBUMOCXXJN-UHFFFAOYSA-N 7-bromo-8-hydroxy-3-(2-methoxyethyl)-2-thiophen-2-yl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C(Br)=CC=C3C=2C(=O)N(CCOC)C=1C1=CC=CS1 RSKOJBUMOCXXJN-UHFFFAOYSA-N 0.000 claims description 4
- IERNYVIIHPXXCC-UHFFFAOYSA-N 8-hydroxy-3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1 IERNYVIIHPXXCC-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- IWWPVLAMLDKZCY-UHFFFAOYSA-N [3-[(5-bromofuran-2-yl)methyl]-4-oxo-2-propyl-[1]benzothiolo[2,3-d]pyrimidin-8-yl] acetate Chemical compound CCCC1=NC=2SC3=C(OC(C)=O)C=CC=C3C=2C(=O)N1CC1=CC=C(Br)O1 IWWPVLAMLDKZCY-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- JZGZKRJVTIRPOK-UHFFFAOYSA-N ethyl thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=CS1 JZGZKRJVTIRPOK-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- XQSDTRVRYXPNAZ-UHFFFAOYSA-N 3-butyl-2-(2,4-difluorophenyl)-8-hydroxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CCCC)C=1C1=CC=C(F)C=C1F XQSDTRVRYXPNAZ-UHFFFAOYSA-N 0.000 claims description 3
- CMIPVAHJRMGCEL-UHFFFAOYSA-N 3-butyl-8-hydroxy-2-(2-methoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CCCC)C=1C1=CC=CC=C1OC CMIPVAHJRMGCEL-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- DRTQHLFDZIQYNT-UHFFFAOYSA-N methyl 2-(3-benzyl-7-tert-butyl-4-oxo-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl)acetate Chemical compound COC(=O)CC1=NC=2SC=3CC(C(C)(C)C)CCC=3C=2C(=O)N1CC1=CC=CC=C1 DRTQHLFDZIQYNT-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 35
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 8
- 229920001577 copolymer Chemical group 0.000 claims 5
- 206010036049 Polycystic ovaries Diseases 0.000 claims 2
- 230000005906 menstruation Effects 0.000 claims 2
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- 125000000950 dibromo group Chemical group Br* 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 229960002847 prasterone Drugs 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
- 238000002366 time-of-flight method Methods 0.000 description 148
- 238000005481 NMR spectroscopy Methods 0.000 description 136
- 238000000034 method Methods 0.000 description 118
- 239000007858 starting material Substances 0.000 description 100
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 41
- 239000011734 sodium Substances 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 37
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 30
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 29
- 239000006227 byproduct Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 23
- 229960005309 estradiol Drugs 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 150000003431 steroids Chemical class 0.000 description 19
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 18
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 description 18
- 102100022585 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 15
- 229930182833 estradiol Natural products 0.000 description 15
- 239000000262 estrogen Substances 0.000 description 15
- 229940011871 estrogen Drugs 0.000 description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 description 13
- 102100022586 17-beta-hydroxysteroid dehydrogenase type 2 Human genes 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 101710174214 Estradiol 17-beta-dehydrogenase 2 Proteins 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 12
- IIQFBBQJYPGOHJ-UHFFFAOYSA-N 4-(cyclohexen-1-yl)morpholine Chemical compound C1CCCC(N2CCOCC2)=C1 IIQFBBQJYPGOHJ-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 108010038795 estrogen receptors Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000003098 androgen Substances 0.000 description 10
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 9
- 102100038595 Estrogen receptor Human genes 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 239000003163 gonadal steroid hormone Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 0 CC(C(*)C1*)C(*)C(*2)=C1C(C1)=C2N=C(*)N(*)C1=O Chemical compound CC(C(*)C1*)C(*)C(*2)=C1C(C1)=C2N=C(*)N(*)C1=O 0.000 description 6
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 102000004026 17-Hydroxysteroid Dehydrogenases Human genes 0.000 description 5
- 108010082514 17-Hydroxysteroid Dehydrogenases Proteins 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 201000004458 Myoma Diseases 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
- 125000004442 acylamino group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 5
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 102000015694 estrogen receptors Human genes 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GFZLEUSLQORNJJ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine 5-oxide Chemical class C1=NC=C2S(=O)C=CC2=N1 GFZLEUSLQORNJJ-UHFFFAOYSA-N 0.000 description 5
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 4
- FEHWURPDQSWPJM-UHFFFAOYSA-N 3-benzyl-2-thiophen-2-yl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C=1C=CSC=1C1=NC=2SC=3CCCCC=3C=2C(=O)N1CC1=CC=CC=C1 FEHWURPDQSWPJM-UHFFFAOYSA-N 0.000 description 4
- WXVXINABPFCQED-UHFFFAOYSA-N 3-benzyl-2-thiophen-2-yl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound O=C1CCCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CS1 WXVXINABPFCQED-UHFFFAOYSA-N 0.000 description 4
- JEDVKUHCDPPWNR-UHFFFAOYSA-N 3h-thieno[2,3-d]pyrimidin-4-one Chemical compound O=C1NC=NC2=C1C=CS2 JEDVKUHCDPPWNR-UHFFFAOYSA-N 0.000 description 4
- 239000004342 Benzoyl peroxide Substances 0.000 description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 229940124639 Selective inhibitor Drugs 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 125000005037 alkyl phenyl group Chemical group 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 229940046836 anti-estrogen Drugs 0.000 description 4
- 230000001833 anti-estrogenic effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000328 estrogen antagonist Substances 0.000 description 4
- 229960003399 estrone Drugs 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- BKBMACKZOSMMGT-UHFFFAOYSA-N methanol;toluene Chemical compound OC.CC1=CC=CC=C1 BKBMACKZOSMMGT-UHFFFAOYSA-N 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- BBWSCERDVFKRLN-UHFFFAOYSA-N 3-(furan-2-ylmethyl)-2-propyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CCCC1=NC=2SC(C(CCC3)=O)=C3C=2C(=O)N1CC1=CC=CO1 BBWSCERDVFKRLN-UHFFFAOYSA-N 0.000 description 3
- OLPXQOVMCKUESX-UHFFFAOYSA-N 3-benzyl-8-chloro-4-oxo-2-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(=C(C=O)CC4)Cl)SC=3N=2)CC=2C=CC=CC=2)=C1 OLPXQOVMCKUESX-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 3
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 3
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- CDYVTVLXEWMCHU-UHFFFAOYSA-N ethyl 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound C1CCCC2=C1SC(N)=C2C(=O)OCC CDYVTVLXEWMCHU-UHFFFAOYSA-N 0.000 description 3
- JHCRHXQSYPTWPT-UHFFFAOYSA-N ethyl 2-amino-7-hydroxy-1-benzothiophene-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OCC)=C(N)SC2=C1O JHCRHXQSYPTWPT-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 210000000754 myometrium Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- RWBRUCCWZPSBFC-SJOKZOANSA-N (20R)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-SJOKZOANSA-N 0.000 description 2
- OLFUPHOOXXQFOK-UHFFFAOYSA-N (3-benzyl-4,8-dioxo-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidin-2-yl)methyl acetate Chemical compound CC(=O)OCC1=NC=2SC(C(CCC3)=O)=C3C=2C(=O)N1CC1=CC=CC=C1 OLFUPHOOXXQFOK-UHFFFAOYSA-N 0.000 description 2
- HGDABRKJGCGDAS-UHFFFAOYSA-N (3-benzyl-7-bromo-4-oxo-2-phenyl-[1]benzothiolo[2,3-d]pyrimidin-8-yl) acetate Chemical compound CC(=O)OC1=C(Br)C=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CC=C1 HGDABRKJGCGDAS-UHFFFAOYSA-N 0.000 description 2
- VYCRIPVKOJTSLP-UHFFFAOYSA-N (4-oxo-3-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl)methyl acetate Chemical compound CC(=O)OCC1=NC=2SC=3CCCCC=3C=2C(=O)N1C1=CC=CC=C1 VYCRIPVKOJTSLP-UHFFFAOYSA-N 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 101710147298 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 description 2
- MPBUVXZOTUEAOE-UHFFFAOYSA-N 2,3-dibenzyl-7-tert-butyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1C(C(C)(C)C)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3CC1=CC=CC=C1 MPBUVXZOTUEAOE-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- AKVFJMJGKHPLQN-UHFFFAOYSA-N 2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(2-methoxyethyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CCOC)C=1C1=CC(OC)=C(OC)C(OC)=C1Br AKVFJMJGKHPLQN-UHFFFAOYSA-N 0.000 description 2
- JAWVDAMHURMGFO-UHFFFAOYSA-N 2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(oxolan-2-ylmethyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC2OCCC2)=C1Br JAWVDAMHURMGFO-UHFFFAOYSA-N 0.000 description 2
- PAWZVZSIHZFIPB-UHFFFAOYSA-N 2-(3,5-dihydroxy-4-methoxyphenyl)-3-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1=C(O)C(OC)=C(O)C=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C(CCCC1)=C1S2 PAWZVZSIHZFIPB-UHFFFAOYSA-N 0.000 description 2
- UYENWHQGTJCFPP-UHFFFAOYSA-N 2-(4,8-dioxo-2-thiophen-2-yl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidin-3-yl)ethyl thiophene-2-carboxylate Chemical compound C=1C=CSC=1C(=O)OCCN(C(C=1C2=C(C(CCC2)=O)SC=1N=1)=O)C=1C1=CC=CS1 UYENWHQGTJCFPP-UHFFFAOYSA-N 0.000 description 2
- GJYPPILDXASUIW-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C(CCCC1)=C1S2 GJYPPILDXASUIW-UHFFFAOYSA-N 0.000 description 2
- CSMKOJLLUVNZOQ-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-phenyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C(CCCC1=O)=C1S2 CSMKOJLLUVNZOQ-UHFFFAOYSA-N 0.000 description 2
- AAGZSRINHXQKML-UHFFFAOYSA-N 2-(4-oxo-2-thiophen-2-yl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-3-yl)ethyl thiophene-2-carboxylate Chemical compound C=1C=CSC=1C(=O)OCCN(C(C=1C=2CCCCC=2SC=1N=1)=O)C=1C1=CC=CS1 AAGZSRINHXQKML-UHFFFAOYSA-N 0.000 description 2
- WZHYLZYZDFSYEI-UHFFFAOYSA-N 2-(7,7-dibromo-4,8-dioxo-2-thiophen-2-yl-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidin-3-yl)ethyl thiophene-2-carboxylate Chemical compound O=C1C(Br)(Br)CCC(C=2C(=O)N3CCOC(=O)C=4SC=CC=4)=C1SC=2N=C3C1=CC=CS1 WZHYLZYZDFSYEI-UHFFFAOYSA-N 0.000 description 2
- MPPUSFBKYXVSHS-UHFFFAOYSA-N 2-(7-bromo-4,8-dioxo-2-thiophen-2-yl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidin-3-yl)ethyl thiophene-2-carboxylate Chemical compound O=C1C(Br)CCC(C=2C(=O)N3CCOC(=O)C=4SC=CC=4)=C1SC=2N=C3C1=CC=CS1 MPPUSFBKYXVSHS-UHFFFAOYSA-N 0.000 description 2
- WHSUXHFTSNTATH-UHFFFAOYSA-N 2-(hydroxymethyl)-3-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OCC1=NC=2SC=3CCCCC=3C=2C(=O)N1C1=CC=CC=C1 WHSUXHFTSNTATH-UHFFFAOYSA-N 0.000 description 2
- KCTINEUOTAIIHL-UHFFFAOYSA-N 2-(methoxymethyl)-3-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COCC1=NC=2SC=3CCCCC=3C=2C(=O)N1C1=CC=CC=C1 KCTINEUOTAIIHL-UHFFFAOYSA-N 0.000 description 2
- XPOVKASSWSSLDX-UHFFFAOYSA-N 2-(methoxymethyl)-3-phenyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COCC1=NC=2SC(C(CCC3)=O)=C3C=2C(=O)N1C1=CC=CC=C1 XPOVKASSWSSLDX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 2
- QTEWWJQYLLNHHE-UHFFFAOYSA-N 2-methyl-3-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CC1=NC=2SC=3CCCCC=3C=2C(=O)N1C1=CC=CC=C1 QTEWWJQYLLNHHE-UHFFFAOYSA-N 0.000 description 2
- JHALVXMWEIDCNP-UHFFFAOYSA-N 2-methyl-3-phenyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CC1=NC=2SC(C(CCC3)=O)=C3C=2C(=O)N1C1=CC=CC=C1 JHALVXMWEIDCNP-UHFFFAOYSA-N 0.000 description 2
- VWXCTFPACYMQDS-UHFFFAOYSA-N 3-(2-methoxyethyl)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC=3CCCCC=3C=2C(=O)N(CCOC)C=1C1=CC(OC)=C(OC)C(OC)=C1 VWXCTFPACYMQDS-UHFFFAOYSA-N 0.000 description 2
- WLYTYFVZUBULNX-UHFFFAOYSA-N 3-(2-methoxyethyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(CCC3)=O)=C3C=2C(=O)N(CCOC)C=1C1=CC(OC)=C(OC)C(OC)=C1 WLYTYFVZUBULNX-UHFFFAOYSA-N 0.000 description 2
- MVJODCUZHBGKAI-UHFFFAOYSA-N 3-(2-methoxyethyl)-2-thiophen-2-yl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC=3CCCCC=3C=2C(=O)N(CCOC)C=1C1=CC=CS1 MVJODCUZHBGKAI-UHFFFAOYSA-N 0.000 description 2
- CIWSNDMNKHZEDT-UHFFFAOYSA-N 3-(2-methoxyethyl)-2-thiophen-2-yl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(CCC3)=O)=C3C=2C(=O)N(CCOC)C=1C1=CC=CS1 CIWSNDMNKHZEDT-UHFFFAOYSA-N 0.000 description 2
- YOMRWQPLRLOXOG-UHFFFAOYSA-N 3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC=3CCCCC=3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1 YOMRWQPLRLOXOG-UHFFFAOYSA-N 0.000 description 2
- PIWJQKSYUVKDIO-UHFFFAOYSA-N 3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(CCC3)=O)=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1 PIWJQKSYUVKDIO-UHFFFAOYSA-N 0.000 description 2
- ZOHCVQINDOJOHV-UHFFFAOYSA-N 3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)CC(C)C)=C1 ZOHCVQINDOJOHV-UHFFFAOYSA-N 0.000 description 2
- RYPPOOQAGAETCB-UHFFFAOYSA-N 3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4)=O)SC=3N=2)CC(C)C)=C1 RYPPOOQAGAETCB-UHFFFAOYSA-N 0.000 description 2
- XJCNFAYHPVHHCV-UHFFFAOYSA-N 3-(furan-2-ylmethyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4)=O)SC=3N=2)CC=2OC=CC=2)=C1 XJCNFAYHPVHHCV-UHFFFAOYSA-N 0.000 description 2
- HUNNJRPAZOOJPB-UHFFFAOYSA-N 3-(furan-2-ylmethyl)-2-propyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CCCC1=NC=2SC=3CCCCC=3C=2C(=O)N1CC1=CC=CO1 HUNNJRPAZOOJPB-UHFFFAOYSA-N 0.000 description 2
- LZYDCGUBNXAXPD-UHFFFAOYSA-N 3-(oxolan-2-ylmethyl)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)CC2OCCC2)=C1 LZYDCGUBNXAXPD-UHFFFAOYSA-N 0.000 description 2
- JXLKZBONACBOME-UHFFFAOYSA-N 3-(oxolan-2-ylmethyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4)=O)SC=3N=2)CC2OCCC2)=C1 JXLKZBONACBOME-UHFFFAOYSA-N 0.000 description 2
- WUROSBWCHFRWAM-UHFFFAOYSA-N 3-(pyridin-3-ylmethyl)-2-(3,4,5-trimethylphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CC1=C(C)C(C)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)CC=2C=NC=CC=2)=C1 WUROSBWCHFRWAM-UHFFFAOYSA-N 0.000 description 2
- UVXLSJHHBLRTOH-UHFFFAOYSA-N 3-[(2-methoxyphenyl)methyl]-2-propyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CCCC1=NC=2SC=3CCCCC=3C=2C(=O)N1CC1=CC=CC=C1OC UVXLSJHHBLRTOH-UHFFFAOYSA-N 0.000 description 2
- BNEIWTXSZZDKFT-UHFFFAOYSA-N 3-[(2-methoxyphenyl)methyl]-2-propyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CCCC1=NC=2SC(C(CCC3)=O)=C3C=2C(=O)N1CC1=CC=CC=C1OC BNEIWTXSZZDKFT-UHFFFAOYSA-N 0.000 description 2
- LLKLVELDILEPPT-UHFFFAOYSA-N 3-[(5-bromo-2-hydroxyphenyl)methyl]-8-hydroxy-2-propyl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CCCC1=NC=2SC3=C(O)C=CC=C3C=2C(=O)N1CC1=CC(Br)=CC=C1O LLKLVELDILEPPT-UHFFFAOYSA-N 0.000 description 2
- CNHKQRNSMFJJRK-UHFFFAOYSA-N 3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC=2OC(Br)=CC=2)=C1 CNHKQRNSMFJJRK-UHFFFAOYSA-N 0.000 description 2
- MIJSYHUMKXEFQH-UHFFFAOYSA-N 3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1Br MIJSYHUMKXEFQH-UHFFFAOYSA-N 0.000 description 2
- HBUFJIKNBMAOPL-UHFFFAOYSA-N 3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-methoxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(OC)=C4SC=3N=2)CC=2C=CC=CC=2)=C1Br HBUFJIKNBMAOPL-UHFFFAOYSA-N 0.000 description 2
- CPNXKOAMDAKUSQ-UHFFFAOYSA-N 3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC=C4SC=3N=2)CC=2C=CC=CC=2)=C1Br CPNXKOAMDAKUSQ-UHFFFAOYSA-N 0.000 description 2
- OXKZOICCNIWGHP-UHFFFAOYSA-N 3-benzyl-2-(3,4,5-trihydroxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OC1=C(O)C(O)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)CC=2C=CC=CC=2)=C1 OXKZOICCNIWGHP-UHFFFAOYSA-N 0.000 description 2
- LODPQKHLOIFTJV-UHFFFAOYSA-N 3-benzyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1 LODPQKHLOIFTJV-UHFFFAOYSA-N 0.000 description 2
- CLSPXKVXATZQDX-UHFFFAOYSA-N 3-benzyl-2-(3-methoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=CC=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)CC=2C=CC=CC=2)=C1 CLSPXKVXATZQDX-UHFFFAOYSA-N 0.000 description 2
- PLXIHHQVGBJKBR-UHFFFAOYSA-N 3-benzyl-2-(3-methoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=CC=CC(C=2N(C(=O)C=3C4=C(C(CCC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1 PLXIHHQVGBJKBR-UHFFFAOYSA-N 0.000 description 2
- JDNWDUUEUOBELL-UHFFFAOYSA-N 3-benzyl-2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C(CCCC1)=C1S2 JDNWDUUEUOBELL-UHFFFAOYSA-N 0.000 description 2
- BLBSEQMNSPZMJT-UHFFFAOYSA-N 3-benzyl-2-(4-methoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C(CCCC1=O)=C1S2 BLBSEQMNSPZMJT-UHFFFAOYSA-N 0.000 description 2
- QXKMHASBNVOUTQ-UHFFFAOYSA-N 3-benzyl-2-(4-methoxyphenyl)-7-methyl-8-phenoxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C1=CC=C(C)C(OC=3C=CC=CC=3)=C1S2 QXKMHASBNVOUTQ-UHFFFAOYSA-N 0.000 description 2
- CHPCEQCCJAFWRL-UHFFFAOYSA-N 3-benzyl-2-(5-bromothiophen-2-yl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound S1C(Br)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C(CCCC1=O)=C1S2 CHPCEQCCJAFWRL-UHFFFAOYSA-N 0.000 description 2
- VHKKOYCAWAPTIB-UHFFFAOYSA-N 3-benzyl-2-(5-bromothiophen-2-yl)-8-hydroxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OC1=CC=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=C(Br)S1 VHKKOYCAWAPTIB-UHFFFAOYSA-N 0.000 description 2
- CAAORZBJACKSKT-UHFFFAOYSA-N 3-benzyl-2-(hydroxymethyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OCC1=NC=2SC=3CCCCC=3C=2C(=O)N1CC1=CC=CC=C1 CAAORZBJACKSKT-UHFFFAOYSA-N 0.000 description 2
- NNWWXFSOPUJMRQ-UHFFFAOYSA-N 3-benzyl-2-(methoxymethyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COCC1=NC=2SC=3CCCCC=3C=2C(=O)N1CC1=CC=CC=C1 NNWWXFSOPUJMRQ-UHFFFAOYSA-N 0.000 description 2
- SIKDQGNHTTWRSW-UHFFFAOYSA-N 3-benzyl-2-(methoxymethyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COCC1=NC=2SC(C(CCC3)=O)=C3C=2C(=O)N1CC1=CC=CC=C1 SIKDQGNHTTWRSW-UHFFFAOYSA-N 0.000 description 2
- WZFMSNIKPXEQRV-UHFFFAOYSA-N 3-benzyl-2-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C=1C=CC=CC=1C1=NC=2SC=3CCCCC=3C=2C(=O)N1CC1=CC=CC=C1 WZFMSNIKPXEQRV-UHFFFAOYSA-N 0.000 description 2
- PJAXSIZTIAQZIE-UHFFFAOYSA-N 3-benzyl-2-phenyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound O=C1CCCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CC=C1 PJAXSIZTIAQZIE-UHFFFAOYSA-N 0.000 description 2
- QPYOQQFCCXHEPL-UHFFFAOYSA-N 3-benzyl-4-oxo-8-phenoxy-2-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(=C(C=O)CC4)OC=4C=CC=CC=4)SC=3N=2)CC=2C=CC=CC=2)=C1 QPYOQQFCCXHEPL-UHFFFAOYSA-N 0.000 description 2
- DLYWJYDANFJOCX-UHFFFAOYSA-N 3-benzyl-4-oxo-8-phenoxy-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=C(C=O)C(OC=5C=CC=CC=5)=C4SC=3N=2)CC=2C=CC=CC=2)=C1 DLYWJYDANFJOCX-UHFFFAOYSA-N 0.000 description 2
- HVQNOVRWOGCYNH-UHFFFAOYSA-N 3-benzyl-4-oxo-8-phenylsulfanyl-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=C(C=O)C(SC=5C=CC=CC=5)=C4SC=3N=2)CC=2C=CC=CC=2)=C1 HVQNOVRWOGCYNH-UHFFFAOYSA-N 0.000 description 2
- CBQMYGCXDHJJTN-UHFFFAOYSA-N 3-benzyl-5-bromo-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4Br)=O)SC=3N=2)CC=2C=CC=CC=2)=C1 CBQMYGCXDHJJTN-UHFFFAOYSA-N 0.000 description 2
- DAEJRVZPMISZNO-UHFFFAOYSA-N 3-benzyl-7,7-dibromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)(Br)CC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1Br DAEJRVZPMISZNO-UHFFFAOYSA-N 0.000 description 2
- UZJKALMHAXCSDB-UHFFFAOYSA-N 3-benzyl-7,7-dibromo-2-(3-bromo-5-methoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=CC(Br)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)(Br)CC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1 UZJKALMHAXCSDB-UHFFFAOYSA-N 0.000 description 2
- SZGBZHQMALWQKM-UHFFFAOYSA-N 3-benzyl-7,7-dibromo-2-(3-methoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=CC=CC(C=2N(C(=O)C=3C4=C(C(C(Br)(Br)CC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1 SZGBZHQMALWQKM-UHFFFAOYSA-N 0.000 description 2
- FCOIAPTVVVCJNK-UHFFFAOYSA-N 3-benzyl-7,7-dibromo-2-(4-methoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C(CCC(Br)(Br)C1=O)=C1S2 FCOIAPTVVVCJNK-UHFFFAOYSA-N 0.000 description 2
- AUKSAEUUCAWDHK-UHFFFAOYSA-N 3-benzyl-7,7-dibromo-2-(5-bromothiophen-2-yl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound S1C(Br)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C(CCC(Br)(Br)C1=O)=C1S2 AUKSAEUUCAWDHK-UHFFFAOYSA-N 0.000 description 2
- QUCDFIZPJHVLKD-UHFFFAOYSA-N 3-benzyl-7,7-dibromo-2-phenyl-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound O=C1C(Br)(Br)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CC=C1 QUCDFIZPJHVLKD-UHFFFAOYSA-N 0.000 description 2
- BVCUGLVMPPRHHO-UHFFFAOYSA-N 3-benzyl-7-(hydroxymethyl)-2-(4-methoxyphenyl)-8-phenoxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C1=CC=C(CO)C(OC=3C=CC=CC=3)=C1S2 BVCUGLVMPPRHHO-UHFFFAOYSA-N 0.000 description 2
- WHMBJFRKPPEOQV-UHFFFAOYSA-N 3-benzyl-7-bromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)CC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1Br WHMBJFRKPPEOQV-UHFFFAOYSA-N 0.000 description 2
- BRVXERSTTHPKCH-UHFFFAOYSA-N 3-benzyl-7-bromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=C(Br)C(O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1Br BRVXERSTTHPKCH-UHFFFAOYSA-N 0.000 description 2
- MHUXOOUHKVCLCH-UHFFFAOYSA-N 3-benzyl-7-bromo-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)CC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1 MHUXOOUHKVCLCH-UHFFFAOYSA-N 0.000 description 2
- ULDRQDFFFNQXRZ-UHFFFAOYSA-N 3-benzyl-7-bromo-2-(3-methoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=CC=CC(C=2N(C(=O)C=3C4=C(C(C(Br)CC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1 ULDRQDFFFNQXRZ-UHFFFAOYSA-N 0.000 description 2
- BAWWUQUWAHUZGC-UHFFFAOYSA-N 3-benzyl-7-bromo-2-(4-methoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C(CCC(Br)C1=O)=C1S2 BAWWUQUWAHUZGC-UHFFFAOYSA-N 0.000 description 2
- DZZXSJKEGLHANE-UHFFFAOYSA-N 3-benzyl-7-bromo-2-(5-bromothiophen-2-yl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound O=C1C(Br)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=C(Br)S1 DZZXSJKEGLHANE-UHFFFAOYSA-N 0.000 description 2
- KRIYXJNTLSPIED-UHFFFAOYSA-N 3-benzyl-7-bromo-2-phenyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound O=C1C(Br)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CC=C1 KRIYXJNTLSPIED-UHFFFAOYSA-N 0.000 description 2
- PKYJISHHPQTSPB-UHFFFAOYSA-N 3-benzyl-7-bromo-8-hydroxy-2-phenyl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OC1=C(Br)C=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CC=C1 PKYJISHHPQTSPB-UHFFFAOYSA-N 0.000 description 2
- KYVABHFXVYWILI-UHFFFAOYSA-N 3-benzyl-7-chloro-2-(2-chloro-3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Cl)CC4)=O)SC=3N=2)CC=2C=CC=CC=2)=C1Cl KYVABHFXVYWILI-UHFFFAOYSA-N 0.000 description 2
- RUYVBGHJZXUEHC-UHFFFAOYSA-N 3-benzyl-8-chloro-2-(2-chloro-3,4,5-trimethoxyphenyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=C(C=O)C(Cl)=C4SC=3N=2)CC=2C=CC=CC=2)=C1Cl RUYVBGHJZXUEHC-UHFFFAOYSA-N 0.000 description 2
- JIJPYMFZQRQEKS-UHFFFAOYSA-N 3-benzyl-8-chloro-2-(methoxymethyl)-4-oxo-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound COCC1=NC=2SC(C(=C(C=O)CC3)Cl)=C3C=2C(=O)N1CC1=CC=CC=C1 JIJPYMFZQRQEKS-UHFFFAOYSA-N 0.000 description 2
- ZEAJKQDSKBQRGY-UHFFFAOYSA-N 3-benzyl-8-ethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound CCOC1=C(C=O)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC(OC)=C(OC)C(OC)=C1 ZEAJKQDSKBQRGY-UHFFFAOYSA-N 0.000 description 2
- QDVKOTFSULVAST-UHFFFAOYSA-N 3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C=4CCCC(O)C=4SC=3N=2)CC=2C=CC=CC=2)=C1 QDVKOTFSULVAST-UHFFFAOYSA-N 0.000 description 2
- LUJUGAFUEKFNRY-UHFFFAOYSA-N 3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1 LUJUGAFUEKFNRY-UHFFFAOYSA-N 0.000 description 2
- YYENACUZLGOJGJ-UHFFFAOYSA-N 3-benzyl-8-hydroxy-2-(3-methoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=CC=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1 YYENACUZLGOJGJ-UHFFFAOYSA-N 0.000 description 2
- KPGXPLUCJJFBNR-UHFFFAOYSA-N 3-benzyl-8-hydroxy-2-phenyl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OC1=CC=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CC=C1 KPGXPLUCJJFBNR-UHFFFAOYSA-N 0.000 description 2
- RFVMPZCTJZNJAC-UHFFFAOYSA-N 3-benzyl-8-methoxy-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(OC)=C4SC=3N=2)CC=2C=CC=CC=2)=C1 RFVMPZCTJZNJAC-UHFFFAOYSA-N 0.000 description 2
- UTAYSTYKSTUBKK-UHFFFAOYSA-N 3-butyl-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC=3CCCCC=3C=2C(=O)N(CCCC)C=1C1=CC(OC)=C(OC)C(OC)=C1 UTAYSTYKSTUBKK-UHFFFAOYSA-N 0.000 description 2
- NGLPEXAUQDYNFM-UHFFFAOYSA-N 3-butyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(CCC3)=O)=C3C=2C(=O)N(CCCC)C=1C1=CC(OC)=C(OC)C(OC)=C1 NGLPEXAUQDYNFM-UHFFFAOYSA-N 0.000 description 2
- XFHQWOGMVXJHCL-UHFFFAOYSA-N 3-butyl-2-thiophen-2-yl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(CCC3)=O)=C3C=2C(=O)N(CCCC)C=1C1=CC=CS1 XFHQWOGMVXJHCL-UHFFFAOYSA-N 0.000 description 2
- HYWGXJAKHPWCPQ-UHFFFAOYSA-N 3-phenyl-2-(3,4,5-trihydroxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OC1=C(O)C(O)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)C=2C=CC=CC=2)=C1 HYWGXJAKHPWCPQ-UHFFFAOYSA-N 0.000 description 2
- JCMSWJPYBQGUKQ-UHFFFAOYSA-N 3-phenyl-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)C=2C=CC=CC=2)=C1 JCMSWJPYBQGUKQ-UHFFFAOYSA-N 0.000 description 2
- MYTQCXFNHQQRME-UHFFFAOYSA-N 3-phenyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4)=O)SC=3N=2)C=2C=CC=CC=2)=C1 MYTQCXFNHQQRME-UHFFFAOYSA-N 0.000 description 2
- KRTYWLYKAMQVQI-UHFFFAOYSA-N 7,7-dibromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-3-(2-methoxyethyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)(Br)CC3)=O)=C3C=2C(=O)N(CCOC)C=1C1=CC(OC)=C(OC)C(OC)=C1Br KRTYWLYKAMQVQI-UHFFFAOYSA-N 0.000 description 2
- LZDSKOPVTYZAAQ-UHFFFAOYSA-N 7,7-dibromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-3-(2-methylbutyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)(Br)CC3)=O)=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1Br LZDSKOPVTYZAAQ-UHFFFAOYSA-N 0.000 description 2
- IPDQHOMJRIQENQ-UHFFFAOYSA-N 7,7-dibromo-2-methyl-3-phenyl-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CC1=NC=2SC(C(C(Br)(Br)CC3)=O)=C3C=2C(=O)N1C1=CC=CC=C1 IPDQHOMJRIQENQ-UHFFFAOYSA-N 0.000 description 2
- PHZHMMJCUNZTGJ-UHFFFAOYSA-N 7,7-dibromo-3-[(5-bromo-2-methoxyphenyl)methyl]-2-propyl-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CCCC1=NC=2SC(C(C(Br)(Br)CC3)=O)=C3C=2C(=O)N1CC1=CC(Br)=CC=C1OC PHZHMMJCUNZTGJ-UHFFFAOYSA-N 0.000 description 2
- WCTBOQVJDRVZNO-UHFFFAOYSA-N 7,7-dibromo-3-[(5-bromofuran-2-yl)methyl]-2-propyl-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CCCC1=NC=2SC(C(C(Br)(Br)CC3)=O)=C3C=2C(=O)N1CC1=CC=C(Br)O1 WCTBOQVJDRVZNO-UHFFFAOYSA-N 0.000 description 2
- HMBDXXFEWIONJC-UHFFFAOYSA-N 7,7-dibromo-3-butyl-2-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)(Br)CC3)=O)=C3C=2C(=O)N(CCCC)C=1C1=CC(OC)=C(OC)C(OC)=C1 HMBDXXFEWIONJC-UHFFFAOYSA-N 0.000 description 2
- CWHQXXIBCKCPOD-UHFFFAOYSA-N 7,7-dichloro-2-(2-chloro-3,4,5-trimethoxyphenyl)-3-(2-methylbutyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Cl)(Cl)CC3)=O)=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1Cl CWHQXXIBCKCPOD-UHFFFAOYSA-N 0.000 description 2
- BFJFBYPGHVIBTC-UHFFFAOYSA-N 7-bromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-3-(2-methoxyethyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N(CCOC)C=1C1=CC(OC)=C(OC)C(OC)=C1Br BFJFBYPGHVIBTC-UHFFFAOYSA-N 0.000 description 2
- ISHJWCPSUHYNRC-UHFFFAOYSA-N 7-bromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-3-(2-methylpropyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)CC4)=O)SC=3N=2)CC(C)C)=C1Br ISHJWCPSUHYNRC-UHFFFAOYSA-N 0.000 description 2
- PBCQMTMPIXTMJU-UHFFFAOYSA-N 7-bromo-2-(2-bromo-3,4,5-trimethoxyphenyl)-3-(oxolan-2-ylmethyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)CC4)=O)SC=3N=2)CC2OCCC2)=C1Br PBCQMTMPIXTMJU-UHFFFAOYSA-N 0.000 description 2
- IUYRPQBPCFCYSL-UHFFFAOYSA-N 7-bromo-2-methyl-3-phenyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CC1=NC=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N1C1=CC=CC=C1 IUYRPQBPCFCYSL-UHFFFAOYSA-N 0.000 description 2
- BZMABIGONIPDNG-UHFFFAOYSA-N 7-bromo-3-(2-methoxyethyl)-2-thiophen-2-yl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N(CCOC)C=1C1=CC=CS1 BZMABIGONIPDNG-UHFFFAOYSA-N 0.000 description 2
- KPSIDHHGSRSFOT-UHFFFAOYSA-N 7-bromo-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)CC4)=O)SC=3N=2)CC(C)C)=C1 KPSIDHHGSRSFOT-UHFFFAOYSA-N 0.000 description 2
- XINLGGNUTGZDPU-UHFFFAOYSA-N 7-bromo-3-[(2-methoxyphenyl)methyl]-2-propyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CCCC1=NC=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N1CC1=CC=CC=C1OC XINLGGNUTGZDPU-UHFFFAOYSA-N 0.000 description 2
- KBBNAIRVUUXCQJ-UHFFFAOYSA-N 7-bromo-3-[(5-bromofuran-2-yl)methyl]-2-(2-bromo-3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Br)CC4)=O)SC=3N=2)CC=2OC(Br)=CC=2)=C1Br KBBNAIRVUUXCQJ-UHFFFAOYSA-N 0.000 description 2
- ISLDBGFKPFKEGN-UHFFFAOYSA-N 7-bromo-3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-propyl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CCCC1=NC=2SC3=C(O)C(Br)=CC=C3C=2C(=O)N1CC1=CC=C(Br)O1 ISLDBGFKPFKEGN-UHFFFAOYSA-N 0.000 description 2
- URGADRBPWPPKMY-UHFFFAOYSA-N 7-bromo-3-butyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N(CCCC)C=1C1=CC(OC)=C(OC)C(OC)=C1 URGADRBPWPPKMY-UHFFFAOYSA-N 0.000 description 2
- WEQGSROXWBHSCH-UHFFFAOYSA-N 7-bromo-8-hydroxy-3-(2-hydroxyethyl)-2-thiophen-2-yl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C(Br)=CC=C3C=2C(=O)N(CCO)C=1C1=CC=CS1 WEQGSROXWBHSCH-UHFFFAOYSA-N 0.000 description 2
- LMFKGUPUNZNTDW-UHFFFAOYSA-N 7-chloro-2-(2-chloro-3,4,5-trimethoxyphenyl)-3-(2-methylbutyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Cl)CC3)=O)=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1Cl LMFKGUPUNZNTDW-UHFFFAOYSA-N 0.000 description 2
- MEAUAXXEQHWESG-UHFFFAOYSA-N 7-chloro-2-(2-chloro-3,4,5-trimethoxyphenyl)-3-(oxolan-2-ylmethyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(C(Cl)CC4)=O)SC=3N=2)CC2OCCC2)=C1Cl MEAUAXXEQHWESG-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IVQXONSWINIKHX-UHFFFAOYSA-N 8-hydroxy-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC(C)C)=C1 IVQXONSWINIKHX-UHFFFAOYSA-N 0.000 description 2
- KHABCFDPXWVPMN-UHFFFAOYSA-N 8-methoxy-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(OC)=C4SC=3N=2)CC(C)C)=C1 KHABCFDPXWVPMN-UHFFFAOYSA-N 0.000 description 2
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 101710174215 Estradiol 17-beta-dehydrogenase 1 Proteins 0.000 description 2
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 2
- 229940122880 Estrogen receptor agonist Drugs 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010065942 Prostaglandin-F synthase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 238000005899 aromatization reaction Methods 0.000 description 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- PBMZEZIAZHDUEO-UHFFFAOYSA-N ethyl 3-benzyl-2-(4-methoxyphenyl)-4-oxo-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carboxylate Chemical compound C=1C=CC=CC=1CN1C(=O)C=2C=3CCC(C(=O)OCC)=CC=3SC=2N=C1C1=CC=C(OC)C=C1 PBMZEZIAZHDUEO-UHFFFAOYSA-N 0.000 description 2
- ROMCYYOFVGNQRB-UHFFFAOYSA-N ethyl 4-oxo-3-phenyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidine-2-carboxylate Chemical compound CCOC(=O)C1=NC=2SC=3CCCCC=3C=2C(=O)N1C1=CC=CC=C1 ROMCYYOFVGNQRB-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 2
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- SLUOULFXRWJXKF-UHFFFAOYSA-N methyl 3-benzyl-4,8-dioxo-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-2-carboxylate Chemical compound COC(=O)C1=NC=2SC(C(CCC3)=O)=C3C=2C(=O)N1CC1=CC=CC=C1 SLUOULFXRWJXKF-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 230000030541 receptor transactivation Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- GRGKQINPJUNCDI-UHFFFAOYSA-N thieno[2,3-d]pyrimidine-2-carbaldehyde Chemical compound N1=C(N=CC2=C1SC=C2)C=O GRGKQINPJUNCDI-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- BBYBMTKUVVVTSE-UHFFFAOYSA-N (3-benzyl-4-oxo-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl)methyl acetate Chemical compound CC(=O)OCC1=NC=2SC=3CCCCC=3C=2C(=O)N1CC1=CC=CC=C1 BBYBMTKUVVVTSE-UHFFFAOYSA-N 0.000 description 1
- 102100022582 (3R)-3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
- 101710120738 (3R)-3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- VKGDBBHRRCHNMK-UHFFFAOYSA-N 1-(8-phenyl-11,12-dihydro-6h-benzo[c][1]benzazocin-5-yl)ethanone Chemical compound C=1C=C2CCC3=CC=CC=C3N(C(=O)C)CC2=CC=1C1=CC=CC=C1 VKGDBBHRRCHNMK-UHFFFAOYSA-N 0.000 description 1
- LIJPUYWRAJPDLJ-UHFFFAOYSA-N 1-benzyl-1,2,3,4-tetrahydronaphthalene Chemical compound C1CCC2=CC=CC=C2C1CC1=CC=CC=C1 LIJPUYWRAJPDLJ-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical class CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- 101710147297 17-beta-hydroxysteroid dehydrogenase type 2 Proteins 0.000 description 1
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 description 1
- KELIOZMTDOSCMM-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1-benzothiophene Chemical class C1C=CC=C2SCCC21 KELIOZMTDOSCMM-UHFFFAOYSA-N 0.000 description 1
- ONVWUSUHIHLQTL-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-3h-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2NC(=O)C=3C=4CCCCC=4SC=3N=2)=C1 ONVWUSUHIHLQTL-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- ZISYJWKREZHOFX-UHFFFAOYSA-N 2-[(3,4-dimethoxyphenyl)methyl]-8-hydroxy-3-(2-pyridin-2-ylethyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1=C(OC)C(OC)=CC=C1CC(N(C1=O)CCC=2N=CC=CC=2)=NC2=C1C1=CC=CC(O)=C1S2 ZISYJWKREZHOFX-UHFFFAOYSA-N 0.000 description 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 1
- LUHVQTIAVRHOCA-UHFFFAOYSA-N 2-benzylthieno[3,2-d]pyrimidine 5-oxide Chemical compound N=1C=C2S(=O)C=CC2=NC=1CC1=CC=CC=C1 LUHVQTIAVRHOCA-UHFFFAOYSA-N 0.000 description 1
- IJJJSNBMFDDFBC-UHFFFAOYSA-N 2-cyanoethyl acetate Chemical compound CC(=O)OCCC#N IJJJSNBMFDDFBC-UHFFFAOYSA-N 0.000 description 1
- LEQAQBFYCMENLP-UHFFFAOYSA-N 2-methoxy-n-phenylacetamide Chemical compound COCC(=O)NC1=CC=CC=C1 LEQAQBFYCMENLP-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YXWJRKXRIXLSFH-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methoxyethyl)benzamide Chemical compound COCCNC(=O)C1=CC(OC)=C(OC)C(OC)=C1 YXWJRKXRIXLSFH-UHFFFAOYSA-N 0.000 description 1
- IVBZTQOOIWVUEK-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methylbutyl)benzamide Chemical compound CCC(C)CNC(=O)C1=CC(OC)=C(OC)C(OC)=C1 IVBZTQOOIWVUEK-UHFFFAOYSA-N 0.000 description 1
- ISESBRZEYWFXAE-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methylpropyl)benzamide Chemical compound COC1=CC(C(=O)NCC(C)C)=CC(OC)=C1OC ISESBRZEYWFXAE-UHFFFAOYSA-N 0.000 description 1
- ALGAPMXFTBJIPJ-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(oxolan-2-ylmethyl)benzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC2OCCC2)=C1 ALGAPMXFTBJIPJ-UHFFFAOYSA-N 0.000 description 1
- BKONUKOICQMWFW-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(pyridin-3-ylmethyl)benzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=NC=CC=2)=C1 BKONUKOICQMWFW-UHFFFAOYSA-N 0.000 description 1
- PCAHHUDNCNWNIG-UHFFFAOYSA-N 3,4,5-trimethoxy-n-phenylbenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C=CC=CC=2)=C1 PCAHHUDNCNWNIG-UHFFFAOYSA-N 0.000 description 1
- XDWBMUOFXOKDNB-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-ylmethyl)-8-hydroxy-2-(2-methoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=CC=CC=C1C(N(C1=O)CC=2C=C3OCOC3=CC=2)=NC2=C1C1=CC=CC(O)=C1S2 XDWBMUOFXOKDNB-UHFFFAOYSA-N 0.000 description 1
- FALRCEOQUHSKGC-UHFFFAOYSA-N 3-(furan-2-ylmethyl)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)CC=2OC=CC=2)=C1 FALRCEOQUHSKGC-UHFFFAOYSA-N 0.000 description 1
- KTOWKFGFWLSVAH-UHFFFAOYSA-N 3-benzyl-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C=4CCCCC=4SC=3N=2)CC=2C=CC=CC=2)=C1 KTOWKFGFWLSVAH-UHFFFAOYSA-N 0.000 description 1
- ZZDHJDWBTRGLLZ-UHFFFAOYSA-N 3-benzyl-4-oxo-8-phenylsulfanyl-2-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(=C(C=O)CC4)SC=4C=CC=CC=4)SC=3N=2)CC=2C=CC=CC=2)=C1 ZZDHJDWBTRGLLZ-UHFFFAOYSA-N 0.000 description 1
- XMNTUMHCOWDSJE-UHFFFAOYSA-N 3-benzyl-8-ethylsulfanyl-4-oxo-2-(3,4,5-trimethoxyphenyl)-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound CCSC1=C(C=O)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC(OC)=C(OC)C(OC)=C1 XMNTUMHCOWDSJE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- OSJPPGNTCRNQQC-UHFFFAOYSA-N 3-phosphoglyceric acid Chemical class OC(=O)C(O)COP(O)(O)=O OSJPPGNTCRNQQC-UHFFFAOYSA-N 0.000 description 1
- ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical class C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- XOJAJRFBOKCXPI-UHFFFAOYSA-N 4-methoxy-n-phenylbenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1 XOJAJRFBOKCXPI-UHFFFAOYSA-N 0.000 description 1
- JCCFKRNCMIHDFF-UHFFFAOYSA-N 4h-cyclohepta[b]thiophene Chemical compound C1C=CC=CC2=C1C=CS2 JCCFKRNCMIHDFF-UHFFFAOYSA-N 0.000 description 1
- JEJQJCKVMQVOHZ-UHFFFAOYSA-N 5,6-dihydro-4h-1-benzothiophen-7-one Chemical class O=C1CCCC2=C1SC=C2 JEJQJCKVMQVOHZ-UHFFFAOYSA-N 0.000 description 1
- QAFMGDDXMIKGEY-UHFFFAOYSA-N 5,6-dimethyl-3h-thieno[2,3-d]pyrimidin-4-one Chemical class N1=CNC(=O)C2=C1SC(C)=C2C QAFMGDDXMIKGEY-UHFFFAOYSA-N 0.000 description 1
- FILWIBNCJYZQTN-UHFFFAOYSA-N 5-oxo-[1]benzothiolo[3,2-d]pyrimidin-8-ol Chemical compound C1=NC=C2S(=O)C3=CC=C(O)C=C3C2=N1 FILWIBNCJYZQTN-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- KUUPACSNDFKNRS-UHFFFAOYSA-N 7-bromo-3-[(5-bromofuran-2-yl)methyl]-2-propyl-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound CCCC1=NC=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N1CC1=CC=C(Br)O1 KUUPACSNDFKNRS-UHFFFAOYSA-N 0.000 description 1
- QRHOTVHBNYWIGU-UHFFFAOYSA-N 7-bromo-3-butyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C(Br)=CC=C3C=2C(=O)N(CCCC)C=1C1=CC(OC)=C(OC)C(OC)=C1 QRHOTVHBNYWIGU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- FDHVLBOUVWGUDD-UHFFFAOYSA-N 8-chloro-2-(4-methoxyphenyl)-4-oxo-3-phenyl-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C(CCC(C=O)=C1Cl)=C1S2 FDHVLBOUVWGUDD-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- JXKQYYMNICQZKC-UHFFFAOYSA-N BC(CCc1c2[s]c(N=C(c3ccccc3)N3CC4=CC=CCC=C4)c1C3=O)(C2=O)Br Chemical compound BC(CCc1c2[s]c(N=C(c3ccccc3)N3CC4=CC=CCC=C4)c1C3=O)(C2=O)Br JXKQYYMNICQZKC-UHFFFAOYSA-N 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- RSBDANMYTBONPE-UHFFFAOYSA-N C=1C=CSC=1.O=C1N=CC=CN1 Chemical class C=1C=CSC=1.O=C1N=CC=CN1 RSBDANMYTBONPE-UHFFFAOYSA-N 0.000 description 1
- XGESROQOHXMCHB-UHFFFAOYSA-N CC(c1c(N=C2COC)[s]c3c1CCCC3=O)N2c1ccccc1 Chemical compound CC(c1c(N=C2COC)[s]c3c1CCCC3=O)N2c1ccccc1 XGESROQOHXMCHB-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- KPIIOYUXRQTOIX-UHFFFAOYSA-N CCc(cc(cc1OC)C(N2CC3OCCC3)=Nc([s]c3c4CCCC3=O)c4C2=O)c1OC Chemical compound CCc(cc(cc1OC)C(N2CC3OCCC3)=Nc([s]c3c4CCCC3=O)c4C2=O)c1OC KPIIOYUXRQTOIX-UHFFFAOYSA-N 0.000 description 1
- UQYNAUJQMOHKNR-UHFFFAOYSA-N COCCN1C(c(cc(c(OC)c2O)OC)c2Br)=Nc([s]c(c2ccc3)c3O)c2C1=O Chemical compound COCCN1C(c(cc(c(OC)c2O)OC)c2Br)=Nc([s]c(c2ccc3)c3O)c2C1=O UQYNAUJQMOHKNR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical class OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001045223 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 2 Proteins 0.000 description 1
- 101000869981 Homo sapiens Dehydrogenase/reductase SDR family member 11 Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- TYVJKLABELOKKT-UHFFFAOYSA-N N-benzyl-3,4,5-trimethoxybenzamide 3,4,5-trimethoxybenzoyl chloride Chemical compound COC=1C=C(C(=O)Cl)C=C(C1OC)OC.C(C1=CC=CC=C1)NC(C1=CC(=C(C(=C1)OC)OC)OC)=O TYVJKLABELOKKT-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZBNABESGYWHFSR-UHFFFAOYSA-N N1=CN=CC2=C1SC1=C2CCC=C1 Chemical compound N1=CN=CC2=C1SC1=C2CCC=C1 ZBNABESGYWHFSR-UHFFFAOYSA-N 0.000 description 1
- JPRQGOLHLUYASO-UHFFFAOYSA-N O=C1C2=C(N=CN1)SC1=C2C=CC=C1OC(CC=1CC(C(=C(C1)OC)OC)(OC)CC1=CC=CC=C1)=O Chemical compound O=C1C2=C(N=CN1)SC1=C2C=CC=C1OC(CC=1CC(C(=C(C1)OC)OC)(OC)CC1=CC=CC=C1)=O JPRQGOLHLUYASO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100022587 Peroxisomal multifunctional enzyme type 2 Human genes 0.000 description 1
- 101710125609 Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 206010036968 Prostatic pain Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- KTPDULWHYJKLDJ-UHFFFAOYSA-N S1C(=CC=C1)C(=O)O.O=C1C2=C(N=C(N1)C=1SC=CC1)SC1=C2CCCC1 Chemical compound S1C(=CC=C1)C(=O)O.O=C1C2=C(N=C(N1)C=1SC=CC1)SC1=C2CCCC1 KTPDULWHYJKLDJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010090932 Vitellogenins Proteins 0.000 description 1
- AMZNRTQMWPOWCJ-UHFFFAOYSA-N [1]benzothiolo[3,2-d]pyrimidine 5-oxide Chemical compound C1=NC=C2S(=O)C3=CC=CC=C3C2=N1 AMZNRTQMWPOWCJ-UHFFFAOYSA-N 0.000 description 1
- LKSAPPYLHIQCPQ-UHFFFAOYSA-N [2-(2-bromo-3,4,5-trimethoxyphenyl)-3-(2-methylpropyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidin-8-yl] acetate Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(OC(C)=O)=C4SC=3N=2)CC(C)C)=C1Br LKSAPPYLHIQCPQ-UHFFFAOYSA-N 0.000 description 1
- JSQYTRJLPGGEQC-UHFFFAOYSA-N [3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidin-8-yl] acetate Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(OC(C)=O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1Br JSQYTRJLPGGEQC-UHFFFAOYSA-N 0.000 description 1
- SWLGGRRPGHOZCV-UHFFFAOYSA-N [3-benzyl-2-(3-methoxyphenyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidin-8-yl] acetate Chemical compound COC1=CC=CC(C=2N(C(=O)C=3C4=CC=CC(OC(C)=O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1 SWLGGRRPGHOZCV-UHFFFAOYSA-N 0.000 description 1
- RFEKYBRZZCZYSS-UHFFFAOYSA-N [3-benzyl-4-oxo-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-8-yl] acetate Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(OC(C)=O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1 RFEKYBRZZCZYSS-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 208000002938 adenomyoma Diseases 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007269 dehydrobromination reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- AYWFFQGZZINDPZ-UHFFFAOYSA-N ethyl 1-benzothiophene-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OCC)=CSC2=C1 AYWFFQGZZINDPZ-UHFFFAOYSA-N 0.000 description 1
- MYGDFSFTVVUJHF-UHFFFAOYSA-N ethyl 2-acetamido-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound C1CCCC2=C1SC(NC(C)=O)=C2C(=O)OCC MYGDFSFTVVUJHF-UHFFFAOYSA-N 0.000 description 1
- CDCGUOVAAKPRKR-UHFFFAOYSA-N ethyl 2-acetamido-6-bromo-7-oxo-5,6-dihydro-4h-1-benzothiophene-3-carboxylate Chemical compound C1CC(Br)C(=O)C2=C1C(C(=O)OCC)=C(NC(C)=O)S2 CDCGUOVAAKPRKR-UHFFFAOYSA-N 0.000 description 1
- CJBGJHJKMOOCQE-UHFFFAOYSA-N ethyl 2-acetamido-7-hydroxy-1-benzothiophene-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C1O CJBGJHJKMOOCQE-UHFFFAOYSA-N 0.000 description 1
- JPJXZTHTKNOGNH-UHFFFAOYSA-N ethyl 2-acetamido-7-oxo-5,6-dihydro-4h-1-benzothiophene-3-carboxylate Chemical compound C1CCC(=O)C2=C1C(C(=O)OCC)=C(NC(C)=O)S2 JPJXZTHTKNOGNH-UHFFFAOYSA-N 0.000 description 1
- XNASJEQIJMDBQN-UHFFFAOYSA-N ethyl 2-amino-1-benzothiophene-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OCC)=C(N)SC2=C1 XNASJEQIJMDBQN-UHFFFAOYSA-N 0.000 description 1
- YDGAUBHNAKCSKF-UHFFFAOYSA-N ethyl 2-anilino-2-oxoacetate Chemical compound CCOC(=O)C(=O)NC1=CC=CC=C1 YDGAUBHNAKCSKF-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000005253 heteroarylacyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OZUAADDJYWWUAD-UHFFFAOYSA-N methyl 3-(benzylamino)-3-oxopropanoate Chemical compound COC(=O)CC(=O)NCC1=CC=CC=C1 OZUAADDJYWWUAD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- PEUKYEPLCRXPHU-UHFFFAOYSA-N n-(furan-2-ylmethyl)-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2OC=CC=2)=C1 PEUKYEPLCRXPHU-UHFFFAOYSA-N 0.000 description 1
- ZYEIVYVBSACWCG-UHFFFAOYSA-N n-(furan-2-ylmethyl)butanamide Chemical compound CCCC(=O)NCC1=CC=CO1 ZYEIVYVBSACWCG-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- VLAPGEODGZEQPC-UHFFFAOYSA-N n-benzyl-2-methoxyacetamide Chemical compound COCC(=O)NCC1=CC=CC=C1 VLAPGEODGZEQPC-UHFFFAOYSA-N 0.000 description 1
- SXOHQCCMROVDRK-UHFFFAOYSA-N n-benzyl-2-methoxybutanamide Chemical compound CCC(OC)C(=O)NCC1=CC=CC=C1 SXOHQCCMROVDRK-UHFFFAOYSA-N 0.000 description 1
- IUHYGONSJUAHBM-UHFFFAOYSA-N n-benzyl-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC=CC=2)=C1 IUHYGONSJUAHBM-UHFFFAOYSA-N 0.000 description 1
- GIDKNTONPHNFRB-UHFFFAOYSA-N n-benzyl-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NCC=2C=CC=CC=2)=C1 GIDKNTONPHNFRB-UHFFFAOYSA-N 0.000 description 1
- GEFZSLMGZREDTO-UHFFFAOYSA-N n-benzyl-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCC1=CC=CC=C1 GEFZSLMGZREDTO-UHFFFAOYSA-N 0.000 description 1
- LKQUCICFTHBFAL-UHFFFAOYSA-N n-benzylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NCC1=CC=CC=C1 LKQUCICFTHBFAL-UHFFFAOYSA-N 0.000 description 1
- WCGCLWNPEQTVSG-UHFFFAOYSA-N n-benzylthiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)NCC1=CC=CC=C1 WCGCLWNPEQTVSG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VMBFKKOESWAMII-UHFFFAOYSA-N n-butyl-3,4,5-trimethoxybenzamide Chemical compound CCCCNC(=O)C1=CC(OC)=C(OC)C(OC)=C1 VMBFKKOESWAMII-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 108091008589 nuclear estrogen receptors Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000004325 uterine smooth muscle cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Joining Of Glass To Other Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47704703P | 2003-06-10 | 2003-06-10 | |
| PCT/EP2004/006230 WO2005032527A2 (en) | 2003-06-10 | 2004-06-09 | Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006527226A JP2006527226A (ja) | 2006-11-30 |
| JP2006527226A5 JP2006527226A5 (https=) | 2007-07-19 |
| JP4605800B2 true JP4605800B2 (ja) | 2011-01-05 |
Family
ID=34421462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515869A Expired - Fee Related JP4605800B2 (ja) | 2003-06-10 | 2004-06-09 | 新規化合物および治療におけるその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7465739B2 (https=) |
| EP (1) | EP1635839B1 (https=) |
| JP (1) | JP4605800B2 (https=) |
| KR (1) | KR20060054189A (https=) |
| CN (1) | CN1791412A (https=) |
| AR (1) | AR044650A1 (https=) |
| AT (1) | ATE479437T1 (https=) |
| AU (1) | AU2004277311B8 (https=) |
| BR (1) | BRPI0411295A (https=) |
| CA (1) | CA2527617A1 (https=) |
| DE (1) | DE602004028934D1 (https=) |
| DK (1) | DK1635839T3 (https=) |
| ES (2) | ES2352552T3 (https=) |
| IL (1) | IL172316A0 (https=) |
| MX (1) | MXPA05012745A (https=) |
| NO (1) | NO20060123L (https=) |
| PL (1) | PL1635839T3 (https=) |
| PT (1) | PT1635839E (https=) |
| RU (1) | RU2412190C2 (https=) |
| SA (1) | SA04250159B1 (https=) |
| SI (1) | SI1635839T1 (https=) |
| TW (1) | TWI349551B (https=) |
| WO (1) | WO2005032527A2 (https=) |
| ZA (1) | ZA200508296B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US20070232628A1 (en) * | 2004-05-06 | 2007-10-04 | Luengo Juan I | Calcilytic Compounds |
| JP2008517061A (ja) * | 2004-10-20 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | 抗腫瘍剤としての化合物及びそれらの使用 |
| BRPI0419229A (pt) * | 2004-12-13 | 2007-12-18 | Solvay Pharm Gmbh | derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica |
| FR2904000A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee |
| FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| DE102007015169A1 (de) * | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
| DE102007040243A1 (de) * | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| CA2772760A1 (en) * | 2008-12-23 | 2010-07-01 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
| WO2012025638A1 (en) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| WO2012119605A1 (en) * | 2011-03-10 | 2012-09-13 | Akar Yahya Ahmed Abdellhafeez Salem | New disperse dye with potent anticancer activity |
| TW201520219A (zh) * | 2013-03-12 | 2015-06-01 | Lilly Co Eli | 咪唑並吡啶化合物 |
| US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| KR20160042873A (ko) | 2013-06-25 | 2016-04-20 | 포렌도 파마 리미티드 | 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체 |
| WO2014207311A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
| EP3089969A2 (en) | 2014-01-03 | 2016-11-09 | Elexopharm GmbH | Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2 |
| WO2015114663A1 (en) | 2014-01-30 | 2015-08-06 | Council Of Scientific & Industrial Research | Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties |
| GB201419102D0 (en) * | 2014-10-27 | 2014-12-10 | Imp Innovations Ltd | Novel compounds |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| US10626140B2 (en) | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
| US20180312493A1 (en) * | 2015-11-04 | 2018-11-01 | Simon Fraser University | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor |
| FI3634975T3 (fi) | 2017-06-08 | 2024-05-03 | Organon R&D Finland Ltd | 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa |
| CN109503572B (zh) * | 2017-09-15 | 2021-10-08 | 上海交通大学 | 一种合成吲哚喹啉类化合物的方法 |
| BR112021010598A2 (pt) | 2018-12-05 | 2021-08-24 | Forendo Pharma Ltd | Compostos, método para preparação de um composto e composição farmacêutica |
| IL315794A (en) * | 2022-04-28 | 2024-11-01 | Enanta Pharm Inc | Pyrimidine containing 17-beta-hydrosteroid dehydrogenase type 13 inhibitors |
| US20250154163A1 (en) * | 2023-10-26 | 2025-05-15 | Enanta Pharmaceuticals, Inc. | Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4742271B1 (https=) * | 1968-06-20 | 1972-10-25 | ||
| US3775027A (en) | 1971-10-01 | 1973-11-27 | Gray Manuf Co Inc | Two-speed pump |
| JPS62132884A (ja) | 1985-12-05 | 1987-06-16 | Mitsubishi Chem Ind Ltd | ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体 |
| EP0364598A4 (en) | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
| US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| JP3783810B2 (ja) | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
| JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| JP4166433B2 (ja) | 1997-09-11 | 2008-10-15 | 第一製薬株式会社 | ホルモン依存性疾患治療剤 |
| TR200002784T2 (tr) * | 1998-03-11 | 2000-12-21 | Endorecherche, Inc | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar |
| WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| AU2001296961A1 (en) | 2000-09-29 | 2002-04-08 | Bayer Pharmaceuticals Corporation | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
| WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
| AR036492A1 (es) | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
| US6750248B2 (en) * | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
-
2004
- 2004-06-07 US US10/861,907 patent/US7465739B2/en not_active Expired - Fee Related
- 2004-06-08 TW TW093116411A patent/TWI349551B/zh not_active IP Right Cessation
- 2004-06-08 AR ARP040101983A patent/AR044650A1/es not_active Application Discontinuation
- 2004-06-09 AT AT04803089T patent/ATE479437T1/de active
- 2004-06-09 DK DK04803089.4T patent/DK1635839T3/da active
- 2004-06-09 SI SI200431535T patent/SI1635839T1/sl unknown
- 2004-06-09 AU AU2004277311A patent/AU2004277311B8/en not_active Ceased
- 2004-06-09 KR KR1020057022958A patent/KR20060054189A/ko not_active Abandoned
- 2004-06-09 RU RU2006100033/04A patent/RU2412190C2/ru not_active IP Right Cessation
- 2004-06-09 PT PT04803089T patent/PT1635839E/pt unknown
- 2004-06-09 CN CNA200480013515XA patent/CN1791412A/zh active Pending
- 2004-06-09 WO PCT/EP2004/006230 patent/WO2005032527A2/en not_active Ceased
- 2004-06-09 BR BRPI0411295-4A patent/BRPI0411295A/pt not_active IP Right Cessation
- 2004-06-09 CA CA002527617A patent/CA2527617A1/en not_active Abandoned
- 2004-06-09 JP JP2006515869A patent/JP4605800B2/ja not_active Expired - Fee Related
- 2004-06-09 PL PL04803089T patent/PL1635839T3/pl unknown
- 2004-06-09 MX MXPA05012745A patent/MXPA05012745A/es active IP Right Grant
- 2004-06-09 EP EP04803089A patent/EP1635839B1/en not_active Expired - Lifetime
- 2004-06-09 DE DE602004028934T patent/DE602004028934D1/de not_active Expired - Lifetime
- 2004-06-09 ZA ZA200508296A patent/ZA200508296B/xx unknown
- 2004-06-09 ES ES04803089T patent/ES2352552T3/es not_active Expired - Lifetime
- 2004-06-12 SA SA4250159A patent/SA04250159B1/ar unknown
- 2004-11-03 ES ES04805369T patent/ES2352554T3/es not_active Expired - Lifetime
-
2005
- 2005-12-01 IL IL172316A patent/IL172316A0/en unknown
-
2006
- 2006-01-09 NO NO20060123A patent/NO20060123L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050038053A1 (en) | 2005-02-17 |
| SA04250159B1 (ar) | 2008-06-21 |
| AR044650A1 (es) | 2005-09-21 |
| ES2352554T3 (es) | 2011-02-21 |
| WO2005032527A3 (en) | 2005-08-04 |
| RU2412190C2 (ru) | 2011-02-20 |
| AU2004277311B8 (en) | 2010-05-27 |
| WO2005032527A2 (en) | 2005-04-14 |
| TWI349551B (en) | 2011-10-01 |
| AU2004277311B2 (en) | 2010-04-29 |
| EP1635839A2 (en) | 2006-03-22 |
| PT1635839E (pt) | 2010-10-12 |
| KR20060054189A (ko) | 2006-05-22 |
| BRPI0411295A (pt) | 2006-08-01 |
| EP1635839B1 (en) | 2010-09-01 |
| PL1635839T3 (pl) | 2011-02-28 |
| CN1791412A (zh) | 2006-06-21 |
| US7465739B2 (en) | 2008-12-16 |
| DE602004028934D1 (de) | 2010-10-14 |
| DK1635839T3 (da) | 2011-01-03 |
| ATE479437T1 (de) | 2010-09-15 |
| ES2352552T3 (es) | 2011-02-21 |
| ZA200508296B (en) | 2007-01-31 |
| IL172316A0 (en) | 2011-08-01 |
| RU2006100033A (ru) | 2007-07-20 |
| AU2004277311A1 (en) | 2005-04-14 |
| WO2005032527B1 (en) | 2005-09-22 |
| TW200509937A (en) | 2005-03-16 |
| CA2527617A1 (en) | 2005-04-14 |
| NO20060123L (no) | 2006-03-09 |
| MXPA05012745A (es) | 2006-05-17 |
| SI1635839T1 (sl) | 2010-12-31 |
| JP2006527226A (ja) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4605800B2 (ja) | 新規化合物および治療におけるその使用 | |
| JP4612628B2 (ja) | １７−β−ヒドロキシステロイドデヒドロゲナーゼのインヒビターとしてのチオフェンピリミジノン | |
| KR101070025B1 (ko) | 신규의 17β-히드록시스테로이드 탈수소효소타입Ⅰ억제제들 | |
| CN1878786B (zh) | 新的I型17β-羟化类固醇脱氢酶抑制剂 | |
| JP4686549B2 (ja) | １７β−ヒドロキシステロイド・デヒドロゲナーゼの阻害剤としての新規な置換チオフェンピリミジノン誘導体 | |
| US7524853B2 (en) | Compounds and their use in therapy | |
| HK1113676A (en) | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE | |
| JPH09169766A (ja) | チエノピリジン誘導体，その製造法および用途 | |
| KR20070106994A (ko) | 17β하이드록시스테로이드 탈수소효소의 저해제로서신규한 치환된 티오펜피리미디논 유도체 | |
| HK1087331B (en) | Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors | |
| MXPA05012871A (en) | Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070531 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100826 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100917 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101004 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131015 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |